Sabroxy supplement for blood sugar control and thinking in mild cognitive impairment
Tests Sabroxy in people with insulin resistance and mild cognitive impairment.
Key facts
- Who runs it
- SF Research Institute, Inc.
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance
- Status
- Recruiting
- People taking part
- 140 people, planned
- Started
- 29 Jan 2026
- Planned end
- 29 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sabroxy®
- Placebo
- Record updated
- 28 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild memory and thinking problems and insulin resistance. People take Sabroxy® or a placebo once a day for 8 weeks.
- Age
- 40 to 80 years, in two groups: 40 - 60 and 61 - 80.
- Sex
- Men and women can join.
- Disease stage
- Mild cognitive impairment (MoCA score less than 26) and insulin resistance. People must be in good general health.
- Earlier treatment
- People cannot join if they regularly take medicines or supplements that affect blood sugar. They also cannot join if they used corticosteroids in the past 4 weeks, or started a long-term medicine in the last 2 months.
- Biomarker or test result
- HOMA-IR value ≥ 2.0 to < 4.0 and fasting glucose 100 to 135 mg/dL (5.6–7.5 mmol/L) at screening.
Main reasons for not taking part
- Pregnant, breastfeeding, or planning a pregnancy
- Immune system disorders, HIV, organ transplant, or medicines that weaken the immune system
- Skin cancer in the past 5 years
- Uncontrolled disease such as diabetes, asthma, epilepsy, high blood pressure or thyroid disease
- Heart or blood vessel event in the last 3 months, or severe depression
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Female or male, adults grouped by age as follows 2 groups of 70 patients each (35 active and 35 placebo ); GROUP 1 = aged 40 - 60, and; GROUP 2 = aged 61 - 80
- In good general health
- Screening HOMA-IR value ≥ 2.0 to < 4.0
- Screening fasting glucose 100 to 135 mg/dL
- Screening MoCA less than 26
Who cannot take part
- Having a history of immunosuppression/immune deficiency disorders (including HIV infection, it has been AIDS, multiple sclerosis, Crohn's disease, rheumatoid arthritis), organ transplant (heart, kidney, etc.), or currently using oral or systemic immunosuppressive medications and biologics (e.g., azathioprine, belimumab, Cimzia®, Cosentyx®, cyclophosphamide, cyclosporine, Enbrel®, Humira®, Imuran®, Kineret®, mycophenolate mofetil, methotrexate, Orencia®, prednisone, Remicade®, Rituxan®, Siliq™, Simponi®, Stelara®, Taltz®) and/or undergoing radiation or chemotherapy as determined by study documentation
- Currently using or having regularly used corticosteroids (systemic or topical, not nasal or ocular) within the past 4 weeks (including but not limited to betamethasone, clobetasol, desoximetasone, diflorasone, fluocinonide, halcinonide, and halobetasol)
- Having started a long-term medication within the last 2 months
- Having participated in any other clinical trial that evaluates or applies interventions to the same body system, organ, or condition being studied in this trial within 12 weeks prior to the screening visit at SFRI or another research facility or doctor's office
- Having been diagnosed with known allergies to any ingredients in the study product
- Relevant history or presence of any medical disorder potentially interfering with this study (e.g., malabsorption, chronic gastrointestinal diseases, severe depression, cardiovascular disease occurrence within the last 3 months, etc.),
- Having a history of skin cancer within the past 5 years
- Having a disease such as asthma, diabetes, epilepsy, hypertension, hyperthyroidism, or hypothyroidism that is not controlled by diet or medication. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc
- Note - Medications for treatment of chronic diseases that do not affect the metabolism of the study product will be permitted and will be judged individually regarding interference with the study by an investigator
- Regular intake of medications or supplements known to affect glucose tolerance
- Breastfeeding, pregnant, or planning to become pregnant during the study, according to the subject's self-report
- Having a pregnant partner or a partner who is planning to become pregnant during the study period or is unwilling or unable to use an acceptable method of contraception
- Having planned surgeries or invasive medical procedures during the study. Non-invasive medical procedures or surgeries will be reviewed for their impact on the study outcome and acceptability by the Investigator or designee
- Currently participating in any other clinical trial at SFRI or another research facility or doctor's office
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
This trial is currently available in United States.
- San Francisco Research InstituteSan Francisco, United StatesContact: Khaleeq RehmanTaking people
About the trial
What the trial wants to find out
This randomized, double-blind, placebo-controlled, 8-week clinical trial is designed to evaluate the effects of Sabroxy®, a standardized extract of Oroxylum indicum bark, on insulin resistance and cognitive function in adults with mild cognitive impairment and insulin resistance.
Read full original descriptionShow less
A total of 120 participants (men and women, aged 40-80 years) who are non-smokers, with fasting glucose levels between 100-135 mg/dL, HOMA-IR value ≥ 2.0 to < 4.0, and a Montreal Cognitive Assessment (MoCA) score below 26, will be enrolled. Eligible participants will be randomized (1:1) to receive either Sabroxy® (250 mg with 5 mg BioPerine®) or placebo, administered orally once daily for 8 weeks.
The primary endpoint is the change in insulin resistance from baseline to Week 8, assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).
The secondary endpoints include changes in:
Cognitive performance, assessed using the Immediate Word Recall, Numeric Working Memory, Cognitive Failures Questionnaire (CFQ), and Montreal Cognitive Assessment (MoCA).
Biomarkers of metabolic and neuronal function, including Brain-Derived Neurotrophic Factor (BDNF), high-sensitivity C-reactive protein (hs-CRP), fasting insulin, fasting glucose, and phosphorylated tau/amyloid beta (p-Tau/Aβ) ratio.
Safety will be assessed through adverse event monitoring, vital signs, and routine clinical laboratory tests.
The study will be conducted at a single site, San Francisco Research Institute (USA), in compliance with the Declaration of Helsinki, ICH-GCP guidelines, and 21 CFR Part 312 (where applicable).
This study seeks to generate clinical evidence supporting the potential of Sabroxy® supplementation to improve glucose tolerance, reduce inflammation, and enhance cognitive function in individuals with early metabolic and neurocognitive dysfunctions.
The 2 groups in the trial
- Dietary Supplement (Sabroxy®)Existing treatment, for comparison
Subjects are to take two capsules with water in the am.
Treatment: Sabroxy®
- Placebo (Inactive capsule)Placebo, for comparison
Subjects are to take two capsules with water in the am.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An 8-week Study Evaluating the Effects of a Dietary Supplement (Sabroxy®) on Insulin Resistance and Cognitive Function in Subjects With Mild Cognitive Impairment and Insulin Resistance
- Plain-language title
- Sabroxy supplement for blood sugar control and thinking in mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07220694, who can take part
- Record updated
- 28 January 2026